Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-1205 combined with enzalutamide or abiraterone/prednisone in metastatic castration-resistant prostate cancer
NCT03480646Phase 2Completed
- Sponsor
- Constellation Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lirametostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Constellation Pharmaceuticals. Started Nov 2017; status: completed.
02
Drugs
lirametostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03480646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480646.